Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis (Q39148284)

9 September 2017

0 references

Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis (English)

1 reference

9 September 2017

1 reference

Yan Hong Shang

1

1 reference

9 September 2017

Yu Zhang

2

1 reference

9 September 2017

Jing Hua Li

3

1 reference

9 September 2017

Peng Li

4

1 reference

9 September 2017

Xi Zhang

5

1 reference

9 September 2017

1 March 2017

1 reference

9 September 2017

1 reference

9 September 2017

9

1 reference

9 September 2017

3

1 reference

9 September 2017

261-272

1 reference

The PD-1 pathway in tolerance and autoimmunity

9 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

PD-1 signaling in primary T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Managing immune checkpoint-blocking antibody side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Ipilimumab in the treatment of metastatic melanoma: management of adverse events.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2016-0147

21 January 2018

Identifiers

DOI

10.2217/IMT-2016-0147

1 reference

9 September 2017

1 reference